Form 4: Promis Neurosciences Inc. Director Neil Cashman Acquires Additional Shares
SEC Form 4 Filing
Neil Cashman, Chief Scientific Officer and Director of ProMIS Neurosciences Inc., reports purchasing 15,000 common shares at $0.973 per share.
Summary
- Neil Cashman, a director and the Chief Scientific Officer of ProMIS Neurosciences Inc., acquired 15,000 common shares on February 10, 2025, at a price of $0.973 per share.
- Following this transaction, Mr. Cashman directly owns 113,304 common shares and indirectly owns 16,617 shares through his spouse.
Sentiment
Score: 6
Explanation: The sentiment is neutral to slightly positive. The purchase of shares by a director can be interpreted as a sign of confidence, but it's a relatively small transaction.
Positives
- A director's purchase of company stock can be seen as a positive signal, indicating confidence in the company's future prospects.
Industry Context
Form 4 filings are standard practice and provide transparency into the transactions of company insiders. This filing indicates a purchase of shares by a director, which is a common occurrence.
Stakeholder Impact
- The purchase may have a slightly positive impact on shareholder sentiment.
Key Dates
| Date | Description |
|---|---|
| 02/10/2025 | Date of transaction: Neil Cashman purchased 15,000 common shares. |
| 02/12/2025 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.